Related Experiment Video

Updated: May 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Angiotensin II blockade and renal protection

Hiroyuki Kobori1, Hirohito Mori, Tsutomu Masaki

  • 1Department of Pharmacology, Faculty of Medicine, Kagawa University, Ikenobe 1750-1, Miki, Kita, Kagawa 761-0793, Japan.

Current Pharmaceutical Design
|November 27, 2012
PubMed

Insights

Angiotensin II receptor blockers (ARBs) protect kidneys in hypertensive patients with chronic kidney disease by improving blood flow and reducing kidney injury. They offer renoprotective effects through multiple complex mechanisms.

Area of Science:

  • Nephrology
  • Pharmacology
  • Hypertension Management

Background:

  • National guidelines recommend renin-angiotensin system inhibitors, specifically angiotensin II type 1 receptor blockers (ARBs), for hypertensive patients with chronic kidney disease.
  • The precise mechanisms behind the renoprotective effects of ARBs are intricate and multifaceted.

Purpose of the Study:

  • To review the pharmacological effects of ARBs within the kidney.
  • To discuss the mechanisms underlying the renoprotective actions of ARBs, particularly in type 2 diabetic nephropathy.

Main Methods:

  • Review of current literature on ARB mechanisms in kidney disease.
  • Analysis of ARB effects on blood pressure, renal hemodynamics, and urinary albumin excretion.

Main Results:

  • ARBs reduce blood pressure via systemic vasodilation, improving kidney disease outcomes.
  • ARB-induced renal vasodilation increases renal blood flow, mitigating renal ischemia and hypoxia.
  • ARBs decrease urinary albumin excretion by lowering intraglomerular pressure and protecting against glomerular injury.
  • ARBs reduce intrarenal angiotensin II levels, inhibiting renal cell and tissue damage.

Conclusions:

  • ARBs exert renoprotective effects through various mechanisms, including improved renal hemodynamics and direct cellular protection.
  • Understanding these mechanisms is crucial for optimizing ARB therapy in chronic kidney disease, especially in diabetic nephropathy.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.